Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyHealthfirst Oral Cancer Coverage Update | OpenPaye…
    Ask Trek AI about this page
    ModifiedHealthfirstPolicy PO-RE-040v5

    Oral Cancer Screening and Testing

    Customize your policy alerts

    Sign up for Healthfirst Policy PO-RE-040v5 alerts

    Get alerted when Policy PO-RE-040v5 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This reimbursement policy governs coverage for oral and oropharyngeal cancer screening, detection, diagnosis, and high-risk HPV tumor-status testing. Coverage criteria depend on the member's benefit coverage at the time of request.

    Policy Summary
    PayerHealthfirst
    PolicyOral Cancer Screening and Testing
    Policy CodePolicy PO-RE-040v5
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewSep 4, 2024
    Next Review DateNot specified
    Key ActionDocument the diagnosis and HPV tumor-status testing performed by p16 immunohistochemistry for newly diagnosed oropharyngeal squamous cell carcinoma.
    SourceLink
    POLICY UPDATE CHANGES

    Noninvasive tests designed to screen for, detect, or diagnose oral cancer, including mRNA CancerDetect and the OmniPathology Oropharyngeal HPV PCR Test, were explicitly identified as not meeting coverage criteria.

    CPT code 87626 was added to the applicable coding section.

    The description for CPT code 87624 was revised.

    CPT codes 81599, 82397, 88341, and 88342 were removed from the policy coding section.

    CPT code 0429U was added through an off-cycle coding modification.

    The policy background, guidelines, recommendations, and evidence-based scientific references were updated without modifying coverage criteria.

    CPT 0429U was added through an off-cycle coding modification effective January 1, 2024.

    The policy title was changed to "Oral Cancer Screening and Testing" after lesion identification systems were placed outside the scope of enforcement.

    Former coverage criteria items 2 and 3 were combined into a single criterion.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Noninvasive oral cancer tests explicitly identified as not covered
    4Testing categories explicitly stated not to meet coverage criteria
    4Applicable laboratory or molecular testing codes
    14High-risk HPV types listed for the oropharyngeal swab test

    Coverage Criteria

    Services not meeting coverage criteria

    The following services do not meet coverage criteria.

    Noncovered oral cancer screening or diagnostic testing: The requested service is a noninvasive test designed to screen for, detect, or diagnose oral cancer; salivary biomarker testing; HPV genotyping; gene-expression profiling; a panel combining genetic risk factors with nongenetic biomarkers; or detection of HPV from an oropharyngeal swab.

    Examples include mRNA CancerDetect™, the OmniPathology Oropharyngeal HPV PCR Test, and OraRisk® HPV.

    HPV tumor-status testing

    Covered when the stated clinical indication and testing method meet the applicable coverage criterion.

    Covered HPV tumor-status testing: Testing for high-risk HPV with either mRNA expression testing for HPV E6/E7 or immunohistochemistry for p16 expression meets coverage criteria when performed to establish HPV tumor status for an individual with oropharyngeal squamous cell carcinoma or with metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node.

    Either listed testing method may satisfy the criterion.

    Noninvasive oral cancer tests

    The following testing does not meet coverage criteria.

    Noninvasive oral cancer screening, detection, or diagnostic testing: Noninvasive tests designed to screen for, detect, or diagnose oral cancer do not meet coverage criteria.

    Examples include mRNA CancerDetect™ and the OmniPathology Oropharyngeal HPV PCR Test.

    Testing that does not meet coverage criteria

    To screen, detect, or diagnose oral cancer, the following testing does not meet coverage criteria:

    Noncovered oral cancer testing methods

    • Salivary biomarker testing, including peptides or proteins, nucleic acids, or metabolites.
    • Genotyping of HPV, including OraRisk® HPV.
    • Gene expression profiling.
    • Panels that incorporate genetic risk factors with nongenetic biomarkers, including mRNA CancerDetect™.
    • Detection of HPV from an oropharyngeal swab, including the OmniPathology Oropharyngeal HPV PCR Test.

    Noninvasive tests designed to screen for, detect, or diagnose oral cancer do not meet coverage criteria.

    Testing used to screen for, detect, or diagnose oral cancer does not meet coverage criteria when it involves salivary biomarkers such as peptides, proteins, nucleic acids, or metabolites; HPV genotyping; gene-expression profiling; or panels combining genetic risk factors with nongenetic biomarkers.

    Clarified examples of noncovered noninvasive testing include mRNA CancerDetect™ and the OmniPathology Oropharyngeal HPV PCR Test. These tests do not meet coverage criteria when used to screen for, detect, or diagnose oral cancer.

    Detection of HPV from an oropharyngeal swab also does not meet coverage criteria when used to screen for, detect, or diagnose oral cancer. The policy separately identifies salivary biomarker testing, HPV genotyping, gene-expression profiling, and combined genetic and nongenetic biomarker panels as noncovered testing methods.

    Applicable Codes and Coding Changes

    Applicable CodesCPT
    87624Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result
    87625Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed
    87626Human papillomavirus (HPV), oropharyngeal swab, 14 high-risk types (i.e., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). Proprietary test: Omnipathology Oropharyngeal HPV PCR Test; Lab/Manufacturer: OmniPathology Solutions, Medical Corporation.
    0296UOncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy. Proprietary test: mRNA CancerDetect; Lab/Manufacturer: Viome Life Sciences, Inc.
    Revision History Coding ChangesCPT
    81599Code removed from the policy coding section; description not provided in the revision history.
    82397Code removed from the policy coding section; description not provided in the revision history.
    88341Code removed from the policy coding section; description not provided in the revision history.
    88342Code removed from the policy coding section; description not provided in the revision history.
    0429UAdded through an off-cycle coding modification; description not provided in the revision history.
    CPT code added in revision historyCPT
    0429UCPT code added through an off-cycle coding modification effective 1/1/2024; a full code description is not provided in this window.

    Provider Documentation and Billing Actions

    Documentation Required

    Follow-up of OralCDx® Results

    Confirm all OralCDx® atypical and positive findings with an incisional biopsy and histology to completely characterize the lesion. Persistent lesions require adequate follow-up evaluations even when the OralCDx® result is negative.

    • Perform confirmatory incisional biopsy and histology for all atypical and positive results.
    • Arrange adequate follow-up for persistent lesions regardless of the test result.
    Documentation Required

    Document HPV Tumor-Status Testing

    For newly diagnosed oropharyngeal squamous cell carcinoma, document HPV tumor status testing. For eligible cervical nodal metastases from an oropharyngeal primary or level II/III SCC of unknown primary, document the clinical diagnosis and the high-risk HPV testing performed, such as p16 immunohistochemistry or mRNA E6/E7 testing.

    • Document the diagnosis of oropharyngeal squamous cell carcinoma or qualifying metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node.
    • Document p16 immunohistochemistry or other high-risk HPV testing performed, including mRNA expression testing for HPV E6/E7 when applicable.

    Clinical Background

    Oral cancer occurs in the oral cavity between the vermilion border of the lips and the junction of the hard and soft palates or the posterior one-third of the tongue. Squamous cell carcinoma is the most common type of oral cancer. Oropharyngeal squamous cell carcinoma may be associated with high-risk HPV, with p16 immunohistochemistry described as a surrogate marker that generally agrees well with HPV E6/E7 mRNA expression. Conventional oral examination followed by scalpel biopsy and histologic assessment remains the standard approach; adjunctive noninvasive and biomarker tests have not demonstrated sufficient evidence for routine oral cancer screening under this policy.

    Definitions

    Oral cancer
    DefinitionCancer occurring in the oral cavity.
    Anterior boundaryBetween the vermilion border of the lips and the junction of the hard and soft palates.
    Posterior boundaryExtends to the posterior one-third of the tongue.
    Potentially malignant disorder (PMD)
    DefinitionA heterogeneous group of potentially malignant conditions.
    Listed exampleErythroplakia.
    Listed exampleNon-homogeneous leukoplakia.
    Policy Summary
    PayerHealthfirst
    PolicyOral Cancer Screening and Testing
    Policy CodePolicy PO-RE-040v5
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewSep 4, 2024
    Next Review DateNot specified
    Key ActionDocument the diagnosis and HPV tumor-status testing performed by p16 immunohistochemistry for newly diagnosed oropharyngeal squamous cell carcinoma.
    SourceLink
    On This Page
    Coverage CriteriaApplicable Codes and Coding ChangesProvider Documentation and Billing ActionsClinical BackgroundDefinitions
  1. p16 testing may be performed on the primary tumor or cervical nodal metastases only when an oropharyngeal primary tumor is present.
  2. Denial Risk

    Noninvasive Oral Cancer Testing Is Not Covered

    Do not submit noninvasive tests designed to screen for, detect, or diagnose oral cancer as covered services. These tests do not meet Healthfirst coverage criteria because published scientific literature does not establish that they are required and beneficial for diagnosis and treatment.

    • mRNA CancerDetect™ does not meet coverage criteria.
    • OmniPathology Oropharyngeal HPV PCR Test does not meet coverage criteria.
    Denial Risk

    Uncovered Adjunctive Testing

    Do not bill adjunctive oral cancer testing that does not meet coverage criteria, including salivary biomarker testing, HPV genotyping, gene-expression profiling, combined genetic and nongenetic biomarker panels, or HPV detection from an oropharyngeal swab.

    • Salivary biomarkers: peptides/proteins, nucleic acids, or metabolites.
    • HPV genotyping, such as OraRisk® HPV.
    • Gene-expression profiling.
    • Panels incorporating genetic risk factors with nongenetic biomarkers.
    • Detection of HPV from an oropharyngeal swab.
    Denial Risk

    Oral Cancer Screening Tests Are Not Covered

    Noninvasive oral cancer screening, detection, and diagnostic tests are not covered. Claims for these services, including mRNA CancerDetect™, OmniPathology Oropharyngeal HPV PCR Test, and similar noninvasive methods, may be denied when the service does not meet coverage criteria.

    • Apply the coverage criteria to claims for tests intended to screen for, detect, or diagnose oral cancer.
    • Do not represent noncovered noninvasive testing as a covered oral cancer diagnostic service.
    Billing Rule

    Coding and Billing Compliance Required

    Follow all applicable coding, billing, reimbursement, modifier, and claim-edit requirements when submitting professional or institutional claims. Failure to follow these requirements could result in claim denial or recoupment of claim payment.

    • Healthfirst claim edits include NCCI, NCD/LCD policies, modifier usage, global surgery and multiple-procedure rules, medically unlikely edits, and duplicate edits.
    • Apply applicable AMA, CMS CPT/HCPCS/ICD-10, National Uniform Billing Editor revenue-coding, CPT Assistant, New York State, and specialty academy guidelines.
    Denial Risk

    Noncovered Oral Cancer Testing Methods

    Claims involving noncovered oral cancer testing methods may be denied when they do not meet coverage criteria. Do not submit salivary biomarker testing, HPV genotyping, gene-expression profiling, or genetic and nongenetic biomarker panels as covered oral cancer screening, detection, or diagnostic services.

    • Salivary biomarker testing, including peptides/proteins, nucleic acids, or metabolites.
    • HPV genotyping, including OraRisk® HPV.
    • Gene-expression profiling.
    • Panels combining genetic risk factors with nongenetic biomarkers.
    Billing Rule

    Claim Denial or Recoupment Risk

    Failure to follow applicable coding, billing, and reimbursement guidelines may result in denial of the claim or recoupment of payment. Reimbursement remains subject to the member's evidence of coverage, applicable state and federal requirements, and the provider participation agreement.

    • Use appropriate coding, modifiers, reimbursement rules, and claim edits for the service reported.
    • A policy description does not guarantee that Healthfirst will cover or pay for the service.
    Listed exampleErosive lichen planus.
    Listed examplesOral submucous fibrosis and actinic keratosis.
    OSCC
    Full termOral squamous cell carcinoma.
    Relationship to oral cavity cancerOSCC is the most common form of oral cavity cancer.